Sellpharm Rudaś Spółka Jawna (KRS 0000734902, NIP 8513226044) is a Polish company, headquartered in Szczecin, Zachodniopomorskie voivodeship. SELLPHARM RUDAŚ operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since June 4, 2018. SELLPHARM RUDAŚ's most recently reported net revenue was 29.6 K PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Sellpharm Rudaś
Identity
- Name
- Sellpharm Rudaś Spółka Jawna
- Legal form
- SPÓŁKA JAWNA
- Founded
- June 4, 2018
- Registry status as of
- June 9, 2026
- Latest entry
- June 9, 2026
- Founding act
- 03.06.2018
Articles of association history (4)
- June 3, 2018: 03.06.2018
- 26 CZERWCA 2018 R., ZMIENIONO §3, §5
- September 24, 2018: 24.09.2018 R. - ZMIENIONO: §3, §4
- September 1, 2023: 01.09.2023R. -PRZYJĘCIE NOWEGO TEKSTU UMOWY SPÓŁKI; 01.09.2023R. - PRZYJĘCIE NOWEGO TEKSTU UMOWY SPÓŁKI W ZWIĄZKU Z PRZYSTĄPIENIEM DO SPÓŁKI NOWYCH WSPÓLNIKÓ I USTĄPIENIEM DOTYCHCZASOWYCH WSPÓLNIKÓW
Activities
Main activity
47.73.ZDispensing chemist in specialised stores
Address and contact
- Address
- UL. ROBOTNICZA, 20A, 71-712, SZCZECIN, POLSKA
- Voivodeship
- ZACHODNIOPOMORSKIE
- District
- SZCZECIN
- KONTAKT@SELLPHARMSPJ.PL
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-15307-49147-GGFTR-23
Risk and payment profile - Sellpharm Rudaś
Credibility rating
89.5 / 100
Very good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/8 yrs
Board changes
0
0/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Sellpharm Rudaś
Founded
June 4, 2018
8 years in operation
Legal form
SPÓŁKA JAWNA
Registry: RejP
Headquarters
SZCZECIN
ZACHODNIOPOMORSKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
N/A
Shareholders
N/A
Board
N/A
Filed years
1 year
2024
Registry entries
25
latest: June 9, 2026
Revenue
29.6 K PLN
2024
Net profit
24.7 K PLN
2024
Assets
53.4 K PLN
2024
Equity
24.7 K PLN
2024
EBITDA
27.2 K PLN
2024
Valuation
168.9 K PLN
Medium confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Sellpharm Rudaś.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
